LifeCycle Pharma Enters Three Distinct Strategic Collaboration Agreements With Global Pharmaceutical Companies

12-Oct-2006

LifeCycle Pharma A/S announced that it has entered into three strategic collaboration agreements with Sandoz Inc. (an affiliate of Novartis AG), Merck Generics (a subsidiary of Merck KGaA of Darmstadt, Germany) and H. Lundbeck A/S.

Sandoz and LifeCycle Pharma have entered into an exclusive development and commercialization agreement regarding the US market with respect to an undisclosed fenofibrate product developed by LifeCycle Pharma. The parties will be jointly responsible for the future development and Sandoz will be solely responsible for later commercialization of the product in the US. LifeCycle Pharma will receive milestone payments and a significant double-digit royalty rate of future sales.

Merck Generics and LifeCycle Pharma have entered into an exclusive development and commercialization agreement regarding the European markets with respect to an undisclosed fenofibrate product developed by LifeCycle Pharma. Merck Generics is currently considering when to initiate the pivotal studies in Europe with the fenofibrate product. Merck Generics will conduct the future development and commercialization of the fenofibrate product, and will be responsible for all costs associated with these activities. LifeCycle Pharma will receive milestone payments in addition to a significant double- digit royalty rate of future sales.

Lundbeck and LifeCycle Pharma have entered into an agreement by which Lundbeck is granted rights to LifeCycle Pharma's MeltDose(R) technology in connection with Lundbeck's further development of two internal pre-clinical CNS-related projects. LifeCycle Pharma will receive milestone payments related to achieved results in the future developments of these projects. Due to the nature of an existing agreement between Lundbeck and LifeCycle Pharma, LifeCycle Pharma will not receive royalties on future possible revenues of these two CNS-related projects.

https://www.bionity.com/en/news/58600/lifecycle-pharma-enters-three-distinct-strategic-collaboration-agreements-with-global-pharmaceutical-companies.html